Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Drops By 60.9%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the recipient of a significant decline in short interest in June. As of June 15th, there was short interest totalling 900 shares, a decline of 60.9% from the May 31st total of 2,300 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 14,700 shares, the short-interest ratio is currently 0.1 days.

Hedge Funds Weigh In On Armata Pharmaceuticals

An institutional investor recently raised its position in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC raised its stake in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) by 80.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,777 shares of the company’s stock after purchasing an additional 14,647 shares during the quarter. SeaCrest Wealth Management LLC owned about 0.09% of Armata Pharmaceuticals worth $137,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 3.57% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Armata Pharmaceuticals in a research note on Wednesday, May 8th.

Armata Pharmaceuticals Stock Down 0.7 %

Shares of ARMP traded down $0.02 during mid-day trading on Friday, hitting $2.75. The company’s stock had a trading volume of 4,615 shares, compared to its average volume of 11,060. Armata Pharmaceuticals has a 52-week low of $1.07 and a 52-week high of $5.26.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.41). The firm had revenue of $0.97 million during the quarter, compared to analysts’ expectations of $1.20 million. Armata Pharmaceuticals had a negative return on equity of 280.95% and a negative net margin of 1,693.47%. As a group, sell-side analysts anticipate that Armata Pharmaceuticals will post -1.9 earnings per share for the current fiscal year.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.